1. Home
  2. EU vs IRWD Comparison

EU vs IRWD Comparison

Compare EU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$1.89

Market Cap

464.5M

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.62

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
IRWD
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.5M
526.7M
IPO Year
2011
2009

Fundamental Metrics

Financial Performance
Metric
EU
IRWD
Price
$1.89
$3.62
Analyst Decision
Strong Buy
Hold
Analyst Count
1
5
Target Price
$4.00
$4.94
AVG Volume (30 Days)
2.7M
2.3M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
1400.00
EPS
N/A
0.15
Revenue
$43,155,000.00
$298,276,000.00
Revenue This Year
$210.21
$57.95
Revenue Next Year
$30.67
$4.39
P/E Ratio
N/A
$26.00
Revenue Growth
N/A
8.88
52 Week Low
$1.01
$0.55
52 Week High
$4.19
$5.78

Technical Indicators

Market Signals
Indicator
EU
IRWD
Relative Strength Index (RSI) 43.05 53.58
Support Level $1.81 $3.07
Resistance Level $2.17 $3.92
Average True Range (ATR) 0.12 0.23
MACD 0.03 0.10
Stochastic Oscillator 58.02 73.77

Price Performance

Historical Comparison
EU
IRWD

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: